Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma

Harbour BioMed and Kelun-Biotech said China’s NMPA approved the IND for HBM7575/SKB575 to treat asthma, following first patient dosing in a Phase 1 atopic dermatitis study. The long-acting bispecific targets TSLP with a second (undisclosed) mechanism and is designed for subcutaneous dosing intervals of 3+ months based on preclinical half-life. Approval clears a second major indication for clinical development, supporting an expanded pipeline and improving near-term clinical visibility.

Analysis

This is more a validation event for a platform than a cash-flow event. The real economic value sits in whether the asset can prove materially longer dosing than existing asthma biologics, because convenience and persistence matter most in chronic respiratory disease; if the interval slips back toward standard monthly/q8w regimens, the differentiation premium disappears quickly. For Harbour BioMed, the announcement is mainly optionality on its discovery engine; for Kelun, it is better viewed as an asset-quality signal that can improve partnership leverage and future deal terms rather than near-term revenue.

The competitive read-through is most relevant for established biologic franchises like REGN/SNY, AMGN/AZN, and GSK, but the threat is structural, not immediate. A true q12w+ subcutaneous profile would attack adherence and clinic-utilization friction, which is where new entrants can take share even without clearly superior efficacy. The bigger second-order effect is on Chinese immunology valuations: if this program progresses cleanly, investors may re-rate other domestic antibody platforms on the expectation that China-origin assets can still produce globally relevant inflammatory franchises.

The main risk is that IND clearance is a low bar and says nothing about human PK, immunogenicity, or whether the undisclosed second target adds enough efficacy to justify bispecific complexity. The catalyst path is long: 1-3 months is mostly sentiment, 6-18 months is first meaningful PK/safety, and only after that does commerciality become visible. The contrarian view is that the market may overpay for the phrase "best-in-class" before there is any human evidence; the more likely outcome is a series of incremental de-risks rather than an immediate rerating.

Key Decisions for Investors

• Do not chase the news flow in 02142.HK or 6990.HK immediately; treat this as a 6-18 month option on platform validation, not a near-term earnings catalyst.
• Conditional long 6990.HK on a pullback only if management can show human PK supporting >8-12 week exposure; if first-in-human data miss that bar, the differentiation thesis should be faded.
• For investors wanting thematic exposure, prefer a basket long in China innovative-biotech leaders with multiple shots on goal over a single-asset bet; the binary risk on early immunology assets remains high.
• Pair-trade idea: long domestic antibody/platform names with credible late-stage execution, short a basket of China biotech names that rely mostly on preclinical optionality; the market should reward measurable de-risking, not press-release science.
• Set a watch item on any mention of severe asthma enrollment, immunogenicity, or dosing interval in the next clinical update; those are the falsifiers for the best-in-class narrative.